• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Pfizer Acquires Seagen For $43B To Tackle Cancer

Share:

March 20, 2023

What You Should Know:

Pfizer announced it will acquire biotechnology company Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion. The proposed combination enhances Pfizer’s position as a leading company in Oncology.

Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio.

Seagen Background

Seagen is a pioneer in ADC technology, with four of the twelve total FDA-approved and marketed ADCs using its technology industry-wide. ADCs are a transformative modality that is emerging as a powerful tool across a broad range of cancers designed to preferentially kill cancer cells and limit off-target toxicities. Seagen has developed a leadership position in ADC technologies since its founding 25 years ago, with groundbreaking and proprietary technology that is positioned for significant growth in 2023 and beyond. Seagen’s portfolio includes four approved medicines2 that are first- or best-in-class in their respective indications across solid tumors and hematologic malignancies, including three ADCs: ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin), and TIVDAK® (tisotumab vedotin). The company also commercializes TUKYSA® (tucatinib). Clinical development programs are ongoing for each of these medicines for potential new tumor types or expanded indications in earlier lines of therapy, with catalysts expected annually through 2027.

Seagen is also poised to expand the impact of its therapeutic approach with its broad and deep pipeline that includes eleven new molecular entities, many with the potential to treat large patient populations and all with global commercial rights.3 The proposed acquisition is also expected to enable for combination potential across both the Seagen and Pfizer pipelines and will leverage Pfizer’s protein engineering and medicinal chemistry capabilities to advance Seagen’s ADC technology to unlock potential novel target combinations and next-generation biologics.

Acquisition Impact

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Seagen expects to generate approximately $2.2 billion of revenue in 20231, representing 12% year-over-year growth, from its four in-line medicines, royalties and collaboration and license agreements. When combining the expected strong growth trajectories for these medicines with candidates that could emerge from Seagen’s pipeline, subject to clinical trial and regulatory success, Pfizer believes Seagen could contribute more than $10 billion in risk-adjusted revenues in 2030, with potential significant growth beyond 2030.

Source: HitConsultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell ScienceCastle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science
  • Hinge Health Expands Capabilities to Launch First Digital Musculoskeletal ClinicHinge Health Expands Capabilities to Launch First Digital Musculoskeletal Clinic
  • FundamentalVR Closes $5M Series AFundamentalVR Closes $5M Series A
  • Varian takes out CyberHeartVarian takes out CyberHeart
  • Medicare 101 for Digital Health Part 2: how Digital Health Companies can Gain Traction in MedicareMedicare 101 for Digital Health Part 2: how Digital Health Companies can Gain Traction in Medicare
  • Federal Street Acquisition Corp., Thomas H. Lee Partners, L.P. and Agiliti Health, Inc. CompleteBusiness CombinationFederal Street Acquisition Corp., Thomas H. Lee Partners, L.P. and Agiliti Health, Inc. CompleteBusiness Combination
  • ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAsANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs
  • New Online Platform for Doctors Launches in IndiaNew Online Platform for Doctors Launches in India

Trending This Week

  • Denials Management Named Most Time-Consuming Task in RCM
  • Why Adopting Value-Based Care Models for Autism Care Is Imperative
  • Why AI-Driven Cancer Screening Will Soon Become Standard of Care
  • Bioventus Completes Divestiture of its Wound Business
  • Enzo Biochem Reports Significant Progress Toward Completing the Clinical Lab Asset Sale
  • eMolecules Acquires Specs Compound Handling B.V.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications